secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0001714899-25-000128
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Therapeutics elects Julian Baker as director; grants registration rights to Baker Brothers funds
--------------------------------------------------------------------------------

- Julian C. Baker elected as Class II director; 98.0M votes for, 22.9M withheld.
- Registration rights agreement with BBA Funds grants resale registration rights; company must file S-3 within 60 days of request.
- Ratified Ernst & Young as independent auditor for FY2025; advisory say-on-pay approved with 90.2% of shares represented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489925000128/0001714899-25-000128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489925000128/dnli-20250603.htm
  HTML page:      https://secwatch.observer/filing/0001714899-25-000128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer